| P50 | author | Joost Bart | Q38329387 |
| | Judith R Kroep | Q56920064 |
| P2093 | author name string | Marc J van de Vijver | |
| | Jelle Wesseling | |
| | Ed Schuuring | |
| | Tim J A Dekker | |
| | Wilma E Mesker | |
| | Vincent T H B M Smit | |
| | Sybren L Meijer | |
| | Gerrit K J Hooijer | |
| | James E Boers | |
| | Joost van Gorp | |
| | Susan Ter Borg | |
| P2860 | cites work | Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. | Q27824766 |
| | Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer | Q27824847 |
| | Lapatinib plus capecitabine for HER2-positive advanced breast cancer | Q27851403 |
| | Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets | Q28140238 |
| | Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer | Q29616112 |
| | Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). | Q33730975 |
| | Estimates of cancer incidence and mortality in Europe in 2008. | Q34095813 |
| | Real-world performance of HER2 testing--National Surgical Adjuvant Breast and Bowel Project experience | Q34669824 |
| | HER2 evaluation using the novel rabbit monoclonal antibody SP3 and CISH in tissue microarrays of invasive breast carcinomas | Q35984457 |
| | American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer | Q36678853 |
| | Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer | Q37117151 |
| | Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 centres. | Q38453048 |
| | Validation of tissue microarray technology in breast carcinoma | Q38462822 |
| | Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization | Q38477505 |
| | A formalin-fixed, paraffin-processed cell line standard for quality control of immunohistochemical assay of HER-2/neu expression in breast cancer | Q40666631 |
| | HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues | Q47612892 |
| | HER-2 testing in breast cancer using parallel tissue-based methods | Q47685189 |
| | Standardization of HER2 testing: results of an international proficiency-testing ring study. | Q51918651 |
| | HER-2/neu in breast cancer: interobserver variability and performance of immunohistochemistry with 4 antibodies compared with fluorescent in situ hybridization. | Q52935808 |
| | Silver in situ hybridization (SISH) for determination of HER2 gene status in breast carcinoma: comparison with FISH and assessment of interobserver reproducibility. | Q53067130 |
| | HER2 and responsiveness of breast cancer to adjuvant chemotherapy. | Q54600960 |
| | c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases | Q71692738 |
| | Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers | Q74195368 |
| | Evaluation of HER-2/neu immunohistochemical assay sensitivity and scoring on formalin-fixed and paraffin-processed cell lines and breast tumors: a comparative study involving results from laboratories in 21 countries | Q74761182 |
| | erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer | Q77331949 |
| | HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial | Q79816337 |
| | HER2 testing in a population-based study of patients with metastatic breast cancer treated with trastuzumab | Q80463670 |
| | Comparative analysis of six different antibodies against Her2 including the novel rabbit monoclonal antibody (SP3) and chromogenic in situ hybridisation in breast carcinomas | Q81261913 |
| | Determination of HER2 amplification by in situ hybridization: when should chromosome 17 also be determined? | Q82665113 |
| P433 | issue | 3 | |
| P304 | page(s) | R93 | |
| P577 | publication date | 2012-06-13 | |
| P1433 | published in | Breast Cancer Research | Q2208481 |
| P1476 | title | Determining sensitivity and specificity of HER2 testing in breast cancer using a tissue micro-array approach | |
| P478 | volume | 14 | |